KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetReceivables - OtherShares Issued
Ratios

Gilead Sciences (GILD) Receivables - Other (2018 - 2025)

Gilead Sciences' Receivables - Other history spans 8 years, with the latest figure at $629.0 million for Q4 2025.

  • For Q4 2025, Receivables - Other rose 127.08% year-over-year to $629.0 million; the TTM value through Dec 2025 reached $629.0 million, up 127.08%, while the annual FY2025 figure was $629.0 million, 127.08% up from the prior year.
  • Receivables - Other reached $629.0 million in Q4 2025 per GILD's latest filing, down from $695.0 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $695.0 million in Q3 2025 to a low of $117.0 million in Q4 2023.
  • Average Receivables - Other over 5 years is $230.8 million, with a median of $169.0 million recorded in 2021.
  • Peak YoY movement for Receivables - Other: tumbled 31.58% in 2023, then skyrocketed 277.72% in 2025.
  • A 5-year view of Receivables - Other shows it stood at $174.0 million in 2021, then dropped by 1.72% to $171.0 million in 2022, then crashed by 31.58% to $117.0 million in 2023, then surged by 136.75% to $277.0 million in 2024, then soared by 127.08% to $629.0 million in 2025.
  • Per Business Quant, the three most recent readings for GILD's Receivables - Other are $629.0 million (Q4 2025), $695.0 million (Q3 2025), and $305.0 million (Q2 2025).